

Message from the President of AfricaBio



The 2020 BIO Africa Convention was framed by the global anti-racism solidarity campaigns and commitment made by the host organisation to use this important platform to advocate for the biotechnology innovation community for inclusion and diversity. It was pointed out that one of the risks of focusing solely on race as a basis of exclusion may miss some important and nuanced forms of exclusion such as class, gender and sexual orientation. The BIO Africa organisation then committed itself to ensuring that its programme deliberately tackles these issues as its modest contribution to the global fight for equality.

When this stand was taken, there was already emerging evidence that one even more dangerous form of exclusion was taking shape. The world was in the beginning of a deadly Covid-19 pandemic, and as the evidence was gathered it became clear

that vaccines are one of the most important tickets to humanity's safety, and hope of returning to normality, albeit new. What has been witnessed in the past year is the appearance of what most have called vaccine nationalism, which is not a new phenomenon. It is simply a manifestation of what BIO Africa Convention has cautioned against since its inception, and was one of the motivating objectives for its launch in the first place.

The 2021 Convention theme was "Advancing Africa's Biomanufacturing Value Chains through Innovation". This is an attempt for Africa to respond to the challenge posed by this pandemic, but more importantly, to galvanise society to create an enabling environment that supports biotechnology innovation to make the continent better prepared for the next pandemic when it occurs. It is not a question of "if", but "when". Africa cannot afford to find itself picking up a number and joining the back of the queue as it waits its turn to receive its vaccine doses. It also can no longer afford to depend solely on charitable donations from across the world to receive its vaccine

doses and other healthcare needs. The theme of the 2021 Convention recognises that while our policy leaders are doing a commendable job to deal with the existential crisis, there is a need for future-proofing strategies, based on several latent capabilities that the continent possesses.

The Convention was arranged according to eight tracks as is tradition, framed by the main biotechnology sectors. These are not exhaustive but chosen mainly in line with our regional context. The Healthcare Track (advancing universal Access through Innovation) addressed directly the current and future challenges. It featured, as expected, dialogue by executives (Aspen and Biovac) who are at the forefront of ensuring that as a continent there is adequate supply in the short to medium term. This was mixed with individuals who represented the aspect of future-proofing (WHO, CSIR), whose contributions focused on innovation, including establishing the correct capacity at upstream value chains such as discovery science.

Excitingly, the WHO has chosen South Africa as the first site of the mRNA Hub, incorporating the different elements from development to manufacturing. The CSIR remains a leading research organisation in the continent, with scale and expertise that can be quickly pivoted, as there is an apparent need to hedge our bets regarding vaccine technology platforms.

Pandemics are not solely dependent on vaccines for management; diagnostics play an important role too. Again, the global value and supply chains are critical in this endeavour. The fact is that there was a serious disruption in the global supply chains during the beginning of the Covid-19 pandemic. The Session of Diagnostics offered real hope for the continent as it featured Innovators based on the continent who have developed and are producing diagnostics to prepare for the next pandemic.

This will avoid replication of the experience of 2020, when global supplies were truncated by the closure of logistics as well as being directed to “home nations”, which are mainly based in the global North.

One of the keynote Innovators, Dr Wendy Steven, has been in the forefront of the HIV epidemic for over two decades. This is an apt reminder that there is still a serious epidemic in our midst. In the 2020 plenary, Professor Salim Abdool Karim emphasised that part of the reason South Africa had managed and continues to manage the HIV challenge was the advent of easy-to-use, lateral flow and molecular diagnostics. It was very encouraging to see green shoots that signalled a move towards self-sufficiency through innovation and entrepreneurship in this aspect. The last two sessions in this track highlighted the importance of internalisation as well as South-South collaboration.

AfricaBio is pleased to announce the appointment of three new board members, Dr Blessed Okole, Dr Mothobi Godfrey Keele and Dr Baty Dungu. Our Board of Directors is comprised of a dedicated team of industry leaders committed to providing direction to grow the African bio-economy. We are excited to channel our new board member’s talent, expertise and energy into furthering our mission.

The BIO Africa Digital Convention 2021 At A Glance



BIO Africa Convention delegates attended from nearly every consumer segment and user industry imaginable, included a large number of decision-makers with budgets to invest from the USA, UK to Africa. As a result, the BIO Africa Convention is an outstanding platform that allows innovators to make new and promising business contacts.

BIO Africa Digital Convention 2021
23rd – 24th August
Advancing Africa's Biomanufacturing Value Chains Through Innovation.

Meet Our Speakers

Looking forward to hearing from women leaders as they discuss biotechnology and innovation.

Ms. Phumtse Mlambo-Ngcika
Under-Secretary-General of the United Nations | Executive Director of UN Women

Dr. Michelle McMurray-Heath
President & CEO of BIO (Biotechnology Innovation Organization)

Dr. Lwazi Nanzol
Head of Secretariat, AU Commission on Africa's COVID-19 Response

Dr. Shongile Gama
Founder/CEO, iNedBio, Board Member Adcock Ingram

Prof. Wendy Stewer
HDB Degree of Molecular Medicine in Haematology, Wits University

Prof. Sam Walker
Principal Researcher Agrometeorology, Agricultural Research Council

Prof. Ginneth Hamba
Founder and Managing Member, Resilience Capital Ventures LLC

Register now for the BIO Africa Digital Convention 2021 taking place on 23rd – 24th August.

Women in Leadership

As nations continued to grapple with issues surrounding the global COVID-19 pandemic, vaccine manufacturing and distribution, the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement found itself in mainstream conversation more than ever before.

The TRIPS waiver is critical in combating the COVID-19 pandemic around the world. Demand for the vaccine has already surpassed supply, with high-income countries taking a large share of reserved doses. Given that no single vaccine manufacturer could produce enough vaccines to meet the demand of the entire globe, supporters of the waiver ponder the ethics of multinational manufacturers holding exclusive rights to information and technology, which prevents other companies from entering the market.

During the plenary session Ms. Xolelwa Mlumbi-Peter, Deputy Director General of International Trade and Economic Development Division at the Department of Trade and Industry, Ms. Anjali Nayyar, Executive Vice President of Global Health Strategies, Dr. Michelle McMurray-Heath, President and CEO of Biotechnology Innovation Organisations in the USA and Bongivi Mlangeni, Senior Director of Global Health Strategies delivered statements on the need of sharing vaccine-related information that will not only help get the pandemic in check now, but could also encourage firms to develop the next round of vaccines that will be necessary in addressing new variants.

Without a TRIPS waiver, the gap between vaccination rates, in high-income and low and middle-income countries (LMIC) will only widen. In order to get 100% of the population vaccinated, there is a greater need for useful and rational solutions that will address the shortage of COVID-19-related health products and technologies.

The Women in Leadership plenary was a great link to the Rising Stars initiative, an initiative that targets young girls that would like to pursue a career in science and innovation. This year's Rising Star's session showcased young African women from the continent and diaspora that are involved in biotechnology and innovation - who shared their experiences and journey into biotechnology innovation and entrepreneurship.

BIO Africa Digital Convention 2021
23rd – 24th August
Advancing Africa's Biomanufacturing Value Chains Through Innovation.

Meet Our Speakers

PLENARY: RISING STARS - bright Young Female Stars of the Future in Biotechnology and Healthcare

Dr. Boltumelo Semete-Makokotlala
CEO of the South African Health Products Regulator Authority (SAHPRA)

Dr. Malendra Umstead
Associate Director, Global Marketing, EMD Serono, Inc.

Ms. Siphokazi Feko
Founder of Brainwave Medical Group

Dr. Thandeka Khoza
Clinical Research Department Manager at Africa Health Research Institute (AHRI)

Dr. Nqobile Gumede
Director, Innovation Office

Ms. Efuwa Edusei
Director of Strategy and Business Development at Sugene

Dr. Sindiswe Muthwa
Researcher on materials chemistry and nanotechnology

Register now for the BIO Africa Digital Convention 2021 taking place on 23rd – 24th August.



Global Biotech Leaders

The BIO Africa convention was closed off with a Dialogue with Global Biotech Leaders, which was facilitated by the President of AfricaBio, Dr. Nhlanhla Msomi. The dialogue featured Nobel Prize winner for medicine, Sir Richard Roberts of New England BioLabs and global leaders in pharmaceutical, vaccine development and production who all share a mission to make the world a better place with the use of biotechnology and future work that will be focused on contributing to the theme of “Advancing Africa’s Biomanufacturing Value Chains through innovation”.

The discussion was on how collaboration is a fundamental aspect in science and the importance of developing an innovation exchange platform to identify intellectual property (IP) availability that will foster tech transfer. The Biotech leaders shared their perspective of accessing critical resources, expertise, finance, clinical trials, regulatory framework, distribution channels, and the value of GMO crops. They also emphasised on the broad acknowledgment and awareness of the public about safety issues in medicine and the need for vaccines, medicines and pharmaceutical drugs to go through the hurdle of safety first before reaching the greater population.

This plenary played a pivotal role in mapping out the drive for future innovation of biotechnology products in the continent and the necessary implications required to fulfill this goal.

BIO Africa Digital Convention 2021
23rd - 24th August
Advancing Africa's Biomanufacturing Value Chains Through Innovation.


Meet Our Speakers

Meet Global Biotechnology Stars

- Prof. Dennis Liotta**
Executive Director, Emory Institute for Drug Development, Emory University
- Dr. Lawrence Banks**
Director General, ICGEB
- Dr. Michelle McMurry-Heath**
BIO (Biotechnology Innovation Organization), President & CEO
- Dr. Yemi Onakunle**
Member, Board of Directors, VLP Biotech
- Sir. Richard Roberts**
Chief Scientific, New England BioLabs, 1993 Nobel Prize Laureate
- Mr. Chris Whitfield**
Executive Director and Regional General Manager for Africa, Gilead Sciences

Register now for the BIO Africa Digital Convention 2021
taking place on 23rd - 24th August.

AFRICA BIO | **science & innovation** | **ELCOTT** | **AMGEN** | **CITI: BioCITI LABS** | **IPASA** | **MailGuard**



BIO Africa 2021 Digital Convention: TIA Academy

In accordance with the theme of the 2021 BIO Africa Digital Convention, “Advancing Africa’s Biomanufacturing Value Chains Through Innovation”, the Technology Innovation Agency’s Product Development Technology Station (PDTs) located at the Central University of Technology (CUT) delivered a training session titled, “Introduction to medical device product development workshop: Developing a sustainable medical device future for South Africa”. The PDTs develops new ideas into products, or improves existing products with detailed engineering, enabling advancement of innovations from concept to prototype. Computer Aided Designs (CAD), Finite Element Analysis, Rapid Prototyping and Reverse Engineering (3D Scanning) are some of the innovative technologies employed by the PDTs.

The current global healthcare crisis resulting from the COVID-19 pandemic, has propelled the advancement of innovative medical device solutions, thereby rendering the PDTs course pertinent and timely. The course was delivered as a side event on Day 2 of the Convention, i.e. 24 August 2021 from 14:00-15:30. Project Assistants, Mzwake Moqhaisa and Thabo Lenkoe, and Junior Project Engineer, Carel Plekker of the PDTs revised a course that would typically include a practical component, and formatted it for digital delivery. The topics included:

- Medical device product development process
- Industrialisation
- Commercialisation opportunities of medical devices in South Africa
- Patient specific medical devices by Additive Manufacturing
- Case study on medical devices in South Africa
- Introduction to medical device registration and ISO 13485
- Introduction to intellectual property and Intellectual Property Rights from Publicly Financed Research and Development (IPR) Act

The course was attended by 34 delegates and has laid a foundation for similar deliveries in future events..



Syndicating Investment in Nuclear Medicine

The Technology Innovation Agency (TIA) hosted a thought leadership session at the BIO Africa Digital Convention 2021 held on 23 and 24 August 2021. The purpose of this industry led session was to identify investment approaches for innovation, growth and sustainability of South Africa’s Nuclear Medicine expertise and infrastructure in order to leverage lucrative opportunities in the global markets.

Nuclear Medicine market is mainly classified into two categories namely diagnosis & therapeutics, that is, its application and end-users. Diagnosis is the largest segment, accounting for 88.6% of global market share in 2013.



The global nuclear medicine market, which includes radioisotopes and medical equipment, was valued at over US\$11-billion in 2016, and is projected to reach nearly US\$20-billion this year (2021). Behind this market is one key medical radioisotope: molybdenum-99 (Mo-99).

Nuclear Medicine market is mainly classified into two categories namely diagnosis & therapeutics, that is, its application and end-users. Diagnosis is the largest segment, accounting for 88.6% of global market share in 2013. The global nuclear medicine market, which includes radioisotopes and medical equipment, was valued at over US\$11-billion in 2016, and is projected to reach nearly US\$20-billion this year (2021). Behind this market is one key medical radioisotope: molybdenum-99 (Mo-99).

South Africa, through Nuclear Technology Products (NTP), a spin-out of the South African Nuclear Energy Corporation (Necsa), is the world's 3rd largest producer of radioisotopes, more so Mo-99, but there remains a fundamental challenge in funding innovation, technology development and capital due to quantum (amounts) of funding required to get to market. This challenge calls for combined efforts in financing this sector and this capitalize in this market through structured partnerships for innovation funding.

The round table discussion was facilitated by Dr. Phehane, Executive Bio-Economy at TIA, addressed key aspects in the benefits of treating cancer patients early nuclear through nuclear medicine technologies, the need to dovetails medical insurance industry' incentives for their clients during and after treatment and to develop a South African case for global industrialization of nuclear medicine products and services.

Other panel members were:

Mr Thabo Tselane, Interim Group Managing Director (Nuclear Technology Products)

Ms Tashinya Naidoo, Fund Manager (Public Investment Cooperation)

Dr Van Rijn Zeevaart, Acting Divisional Executive: R&D (Nuclear Energy Cooperation of South Africa)

Prof. Mike Sathekge (Steve Biko Academic Hospital, Pretoria)

The Nuclear Technologies in Medicine and the Biosciences Initiative (NTeMBI), is a research and development on nuclear technologies in medicines and biosciences infrastructure, is an investment made by the South African Government that will be strengthened through this initiative.

ICGEB tours Durban

Director-General of the ICGEB, Dr Lawrence Banks, announced at the 2021 BIO Africa Convention an initiative that will bring enormous improvements to the lives of patients. The ICGEB, an intergovernmental organisation dedicated to advanced research and training in molecular biology, biotechnology, advancing knowledge and applying the latest techniques in the fields of Biosimilars, Biopesticide and Bioenergy seeks to



enter into strategic partnerships with the National Bioproducts Institute (NBI) KwaZulu Natal Research Innovation and Sequencing Platform (KRISP UKZN) and the Technology Innovation Agency (TIA) as an output of the BIO Africa Digital Convention hosted by AfricaBio.

The ICGEB's main objective is to increase access to Biosimilars through fostering internal domestic production capacity in the field of biopharmaceuticals in ICGEB Member States, with the aim of achieving targets set towards good health and wellbeing, innovation, infrastructure and reducing inequalities. This strategic partnership in the biotechnology industry will allow these KZN technology-based organisations to gain a foothold in Biosimilar discoveries and advances in science for the purpose of public commercial use.

The National Bioproducts Institute (NBI) is a pharmaceutical manufacturer. Its core business is the manufacture of biopharmaceutical products from human plasma into derived medicinal products. The institute also develops and manufactures diagnostics kits and monoclonal antibodies for the South African and international diagnostic market.

“Partnerships that help with growth and scientific impact that create societal mandates and impact communities are essential,” said Professor Mosa Moshabela. A partnership between KRISP UKZN and ICGEB will be seen in pre-clinical and clinical trials that go with Biosimilars rollout, while the Technology Innovation Agency will play a role in the capacity to translate a greater proportion of Biosimilars

research and development into potential commercial technology products.

In industries such as healthcare and biotechnology, the high cost of commercialisation makes it difficult for research to succeed on its own. To overcome this challenge the ICGEB aims to form partnerships and collaborations in Africa whereby therapeutic reagents and diagnostic kits can be produced locally, which will cater to the African population at an affordable prices.



ICGEB and BIO Africa Academy

ICGEB was a proud partner of the BIOAfrica Convention held in Durban, South Africa. This is the premier gathering for promoting research, training and delivery of biotechnological products to Africa, and scientists from ICGEB Trieste, New Delhi and Cape Town were active contributors to sessions covering food security, Biotherapeutics, diagnostics and biofuels.

In synergy with the Convention's goal of the advancement of biotechnology development in Africa, the BIOAfrica Academy and ICGEB hosted a course on 'Biological and biosimilar medicines'. During the BIOAfrica Convention, there was a total number of 149 attendees on day 1 and a total number 24 attendees on day 2.

Lectures and engaging sessions were given by researchers from the Biotechnology Development Unit (BDU), including Group Leader, Dr. Natasa Skoko, Dr. Corrado Guarnaccia and Dr. Michela Terdoslavich. A great turnout of over

BIO Africa Digital Convention 2021
23rd – 24th August
Advancing Africa's Biomanufacturing
Value Chains Through Innovation.

BIO Africa Academy
ICGEB will be a part of the BIO Africa Academy 2021,
Presenting a courses on:

- 1 Biosimilars**
Development of technologies
for production of quality control of biosimilars
- 2 Biopesticides**
Challenges to the adoption of biopesticides in
agriculture: exploring solutions
- 3 Bioenergy**
Advances in Industrial Biotechnology for
second generation renewable fuels

Register for the BIO Africa Digital
Convention 2021 to be part of the
BIO Africa Academy.

AFRICA BIO | AMGEN | CITI | IPASA | ICGEB | NBI | TIA


170 participants included diverse role-players working in Africa, ranging from local and multinational pharmaceutical manufacturers to regulatory authorities.

With the objective to provide an overview of data on biological and biosimilar medicines, the ICGEB shared its experiences in promoting the local production of biologics/biosimilars. The course topics included development of the technologies for the production and quality control of biologics/biosimilars, an overview of the production process for biologics, chemically modified biologics/biosimilars, the design of a manufacturing facility following GMP requirements and Quality Assurance Principles, and the transfer of know-how to the industry in the field of biosimilars to strengthen local capacities and competences.

Looking to the future, the ICGEB and BIOAfrica continue to work together for the advancement of biotechnology development in Africa, focusing on technologies to produce biotherapeutic products, and increasing the know-how and capabilities of the pharmaceutical industries in South Africa and the greater African continent.

ICGEB Director-General, Dr. Lawrence Banks headed the ICGEB delegation, which included Dr. Luiz Zerbini, Acting Director, ICGEB Cape Town, Dr. Navin Khanna, Recombinant Diagnostics and Vaccines, ICGEB New Delhi, Dr. Vittorio Venturi, Bacteriology lab Trieste, Dr. Dennis Ndolo, and Dr. Lara Donaldson, ICGEB Cape Town, and members of the BDU headed by Dr Natasa Skoko.

ICGEB Science and the City



ICGEB, in partnership with BioAfrica, will be hosting the first Science and The City South Africa event in Cape Town in early 2022.

The first international edition of ICGEB's popular public engagement model will be on 'Myth busters: Discrediting misinformation in Science'.

Watch this space for more information on how to attend and register online [#ScienceandtheCity](#) [#ICGEB](#) [#BioAfrica](#) [#fightingmisinformation](#)

Handing over and cultivation of potato seeds/mini tubers to smallholder farmers within the city of eThekweni

The United Nations' (UN) Sustainable Development Goal (SDG2) aims to achieve "zero hunger", by "Ending hunger, achieving food security and improving nutrition and promoting sustainable agriculture" furthermore, the South African government has put in place The National Food and Nutrition Security Plan 2018-2023 (NFNS Plan), which is being used to overcome challenges of food insecurity and malnutrition.

Smallholder farmers play an important role in achieving global food security, nutrition, and reducing poverty. The viability of smallholder farming can be improved by ensuring farmers adopt new technologies to increase production and, consequently, ensure food security and nutrition, reduce rural poverty, and contribute to the achievement of multiple SDGs.

AfricaBio collaborated with the City of eThekweni to establish a potato nursery at the Northdene Agro-Ecology Hub, in the eThekweni Municipality. Seed potatoes/Mini tubers were produced from two potato cultivars (ARC/301 and ARC/302) provided by the Agricultural Research Council (ARC). These seeds will be handed over to smallholder farmers within the eThekweni municipality. Prior to the handing over, the beneficiaries will attend a training course to learn about the best agronomic practices for potato production.

The mini-tubers provided are certified disease-free seeds that can be propagated up to five generations. This benefits the farmers by offsetting the high seed cost of potato seeds over several planting seasons.

AfricaBio is committed to assisting smallholder farmers improve their crop production as this will increase their agricultural income and reduce poverty, improving nutrition and alleviate food insecurity.

The City of eThekweni Municipality partnered with AfricaBio to establish a potato seed nursery at the Northdene Agri-Ecology Hub. Join us to learn about the value and impact of the project to local smallholder farmers, and the future of potato production in eThekweni.

CASE STUDY:
eThekweni Small-scale Farmer Biotechnology Adoption & Sustainable Farming Model: The City of eThekweni & AfricaBio Partnership.

Date: 23 August 2021
Time: 11H00 – 12H00

To RSVP for this side event please join using the following link:
<https://app.glueup.com/event/bio-africa-digital-convention-2021-40600/>

In Celebration of Heritage Month: Indigenous Knowledge Systems is the one tool that Africans possess.

African Natural Medicines

The African Union’s Agenda 2063, the South African National Development Plan and White Paper on Science, Technology and Innovation recognise the potential of African Indigenous Knowledge Systems (IKS) for socio-economic development. IKS is the one tool that Africans possess; and therefore, have competitive advantage through inclusive innovation; to develop new knowledge, products and enterprises. It should therefore be seen as a unifying force, especially for manufacturing and commercialisation of health and wellness products such as African Natural Medicines, Cosmeceuticals, Nutraceuticals and Health Infusions. This strategic partnership in the biotechnology industry will allow these KZN technology-based organisations to gain a foothold in Biosimilar discoveries and advances in science for the purpose of public commercial use. The African continent should take advantage of its innovation capacity, unique biodiversity and untapped IKS to conduct collaborative research, using uBuntu as a driving force for wealth and job creation, poverty alleviation, reversal of inequality and ultimately improved quality of life and thriving societies. The African Free Trade initiative in the region offers an opportunity to researchers, innovators and entrepreneurs to produce an intellectual property that would be owned by Africans, both on the continent and African diaspora. This theme should therefore project a post-Covid 19 vision; where Africa builds African institution for cutting-edge research and world-class manufacturing.



Looking forward to the BIO Africa Convention 2022!

BIO Africa Digital Convention 2021
23rd – 26th August
Advancing Africa's Biomanufacturing Value Chains Through Innovation

The BIO Africa Fellowship Program

AfricaBio is launching the BIO Africa Fellowship Program at this year's Convention.

The Program will encompass a Fellowship that honors the late Ambassador Dr. Konji Sebati who was the CEO of IPASA and AfricaBio Board Member.

The Dr Konji Sebati Female Leaders of Tomorrow will offer Young Female Scientists a combination of work experience that is focused on several tracks within the business of science, from innovation management, strategy, finance, communications to scientific innovation policy. The Dr Konji Sebati Female Leaders of Tomorrow Fellowship is open to young female scientists with a minimum requirement of a BSc Honours or post-graduate.

In honour of the late Ambassador Dr. Konji Sebati

For more information contact us at: info@bioafricaconvention.com



BIO Africa Digital Convention 2021
23rd – 26th August
Advancing Africa's Biomanufacturing Value Chains Through Innovation

The BIO Africa Monthly

Issue 1 | August 2021

AFRICABIO AMGEN IPASA



BIO Africa Digital Convention 2021
23rd – 26th August
Advancing Africa's Biomanufacturing Value Chains Through Innovation

In celebration of Women's Month

We are honoured to have Dr. Phumzile Mlambo-Nguku, United Nations Under-Secretary-General, Executive Director of UN Women and Former Deputy President at this year's BIO Africa Digital Convention.

She brings a wealth of experience and expertise as a champion of women's rights, devoted to education, women's empowerment and gender equality.

Dr. Phumzile Mlambo-Nguku

Bi-Inspired and empowered as Dr. Phumzile Mlambo-Nguku joins the BIO Africa Digital Convention this Tuesday, 24th August during the Launch of the Dr. Konji Sebati Fellowship.



BIO Africa Digital Convention 2021
23rd – 26th August
Advancing Africa's Biomanufacturing Value Chains Through Innovation

The Mandela Scholarship

The Mandela Scholarship, started at University of Sussex in 1973 will offer a full tuition for a Fellow who successfully completes their one year Program.

The Fellow is expected to return to the continent after graduation and continue contributing to the goals of building biotechnology innovation for African development in the areas of healthcare, food security and other life sciences related fields.

US University of Sussex

For more information contact us at: info@bioafricaconvention.com